ABSTRACT
Little is known about gender differences in the symptom burden of people living with HIV/AIDS (PLWHA) on antiretroviral therapy in China. This study was conducted based on a biopsychosocial-medical model to describe gender differences in symptom burden among 1035 PLWHA in Yunnan Province, China. After propensity score matching, 798 PLWHA were included in this analysis. Feeling stressed, poor sleep, and memory loss were the most burdensome symptoms among men, while feeling stressed, memory loss, and dizziness were the most burdensome symptoms among women. Among men PLWHA, factors associated with symptom burden were being of the ethnic minority, CD4 count ≥ 500 cells/mm3, physical functioning, and social support. Among women PLWHA, factors associated with symptom burden were being an inpatient, physical functioning, psychological functioning, and social support. Our findings suggest that healthcare providers need to take into account gender differences when developing optimal prevention, treatment, and care programs that provide individualized care to reduce patients’ symptom burden.
Sustainable Development Goals:
Acknowledgements
The authors would like to thank all of the respondents and the staff who contributed to the data collection.
Availability of data and materials
The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. Email: [email protected].
Disclosure statement
No potential conflict of interest was reported by the author(s).
Ethics approval and consent to participate
The researchers adhered to the principles of the Helsinki Declaration throughout the study. Participants in our study were fully informed of the purpose and potential benefits of this study. This information was collected after informed consent was obtained from each participant, and participation in this study was voluntary with the right to withdraw from the study at any time. This study was approved by the Ethics Committee of the School of Nursing, Fudan University (IRB #TYSA2016-3-1).